Cyclo Therapeutics logo

Cyclo TherapeuticsNASDAQ: CYTH

Profile

Sector:

Healthcare

Country:

United States

IPO:

03 May 2000

Next earnings report:

14 August 2024

Last dividends:

N/A

Next dividends:

N/A
$34.62 M
-46%vs. 3y high
30%vs. sector
-vs. 3y high
-vs. sector
-30%vs. 3y high
99%vs. sector
-53%vs. 3y high
88%vs. sector

Price

regular market | Tue, 02 Jul 2024 13:30:00 GMT
$1.21+$0.01(+0.83%)

Dividend

No data over the past 3 years
$202.40 K$270.00 K
$202.40 K-$4.34 M

Analysts recommendations

Institutional Ownership

CYTH Latest News

Cyclo Therapeutics Achieves Landmark Milestone with Completion of Enrollment of Last Patient in Phase 3 Pivotal TransportNPC™ Trial of Niemann-Pick Type C1
businesswire.com30 May 2024 Sentiment: POSITIVE

GAINESVILLE, Fla.--(BUSINESS WIRE)--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today announced the last patient has been enrolled in the Company's pivotal Phase 3 study (“TransportNPC™”) evaluating Trappsol® Cyclo™ for the treatment of systemic and neurological symptoms of Niemann-Pick Disease.

Cyclo Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
businesswire.com16 May 2024 Sentiment: POSITIVE

Cyclo Therapeutics, Inc. (Nasdaq: CYTH), a biotechnology company focused on developing transformative medicines for patients with diseases, announced its financial results for the first quarter of 2024 and gave an update on its business activities, including advancements in patient enrollment for the TransportNPC™ trial.

What type of business is Cyclo Therapeutics?

Cyclo Therapeutics, Inc., a clinical stage biotechnology company, develops cyclodextrin-based products for the treatment of various diseases. Its lead drug candidate is Trappsol Cyclo, an orphan drug, which is Phase III clinical trials for the treatment of Niemann-Pick Type C disease. The company also develops Trappsol Cyclo for the treatment of Alzheimer's disease. In addition, it sells cyclodextrins and related products to the pharmaceutical, nutritional, and other industries, primarily for use in diagnostics and specialty drugs. The company was formerly known as CTD Holdings, Inc. and changed its name to Cyclo Therapeutics, Inc. in September 2019. Cyclo Therapeutics, Inc. was incorporated in 1990 and is based in Gainesville, Florida.

What sector is Cyclo Therapeutics in?

Cyclo Therapeutics is in the Healthcare sector

What industry is Cyclo Therapeutics in?

Cyclo Therapeutics is in the Drug Manufacturers - Specialty & Generic industry

What country is Cyclo Therapeutics from?

Cyclo Therapeutics is headquartered in United States

When did Cyclo Therapeutics go public?

Cyclo Therapeutics initial public offering (IPO) was on 03 May 2000

What is Cyclo Therapeutics website?

https://www.cyclotherapeutics.com

Is Cyclo Therapeutics in the S&P 500?

No, Cyclo Therapeutics is not included in the S&P 500 index

Is Cyclo Therapeutics in the NASDAQ 100?

No, Cyclo Therapeutics is not included in the NASDAQ 100 index

Is Cyclo Therapeutics in the Dow Jones?

No, Cyclo Therapeutics is not included in the Dow Jones index

When does Cyclo Therapeutics report earnings?

The next expected earnings date for Cyclo Therapeutics is 14 August 2024